Mena FN

Recursion Announces First Patient Dosed In Phase 2 Clinical Study Of REC-3964, A Potential First-In-Class, Oral, Non-Antibiotic Small Molecule For Recurrent Clostridioides ...

REC-3964 is Recursion's first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and blocks ...